Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. by de Serres, Frederick J
Alpha-1 antitrypsin (AAT) deficiency is a
common fatal genetic disease characterized by
clinical manifestations primarily in the lung
and liver [Brantly et al. 1988; Crystal 1996;
World Health Organization (WHO) 1996].
It is commonly regarded as a disease of white
northern Europeans. There are extensive data
in the literature on the prevalence of the two
most common deﬁciency alleles, indicated by
Pi phenotypes PiS and PiZ, in countries all
over Europe (Blanco et al. 2001; Hutchison
1988). Although AAT deﬁciency is thought to
occur predominately in white northern
Europeans of phenotype PiZZ, new data
demonstrate that it affects major racial groups
worldwide and that the numbers and pheno-
typic classes at risk in other countries are much
greater than originally thought (de Serres
2002). Because of the differences in the popu-
lation sizes of different countries, the highest
numbers of individuals of phenotype PiZZ are
actually found in North America, southern
Europe, and Central Asia (de Serres 2002).
These new data (de Serres 2002) indicate that
in a total population of 4.4 billion in the 58
countries surveyed, there are at least 116 mil-
lion carriers (PiMS and PiMZ) and 3.4 mil-
lion with deﬁciency allele combinations (PiSS,
PiSZ, and PiZZ).
There are no data on genetic epidemio-
logic studies of AAT deﬁciency in countries in
the Caribbean such as Puerto Rico or coun-
tries in Central and South America where the
numbers of immigrants from countries in
southern Europe is high (de Serres 2002).
Therefore, the numbers at risk for AAT deﬁ-
ciency worldwide are expected to be much
higher. Furthermore, this database demon-
strates that AAT deﬁciency is found in vari-
ous populations of African blacks; Arabs and
Jews in the Middle East; and Central, Far
East, and Southeast Asians; as well as whites
in northern Europe and their descendents in
Australia, New Zealand, and North America.
In addition, these new data indicate that
there are marked racial and ethnic differences
in the gene frequencies and prevalence of the
PiS and PiZ alleles worldwide (de Serres
2002).
The impression that AAT deficiency is a
rare disease has resulted in infrequent orders
for tests for AAT deficiency even for many
white patients who present with allergy,
asthma, or pulmonary problems, and essen-
tially no orders for tests for patients from other
major racial groups. These findings on the
prevalence of AAT deficiency worldwide are
expected to affect the diagnosis of individuals
with AAT deﬁciency by the medical commu-
nity with the realization a) that it is not a rare
disease worldwide, and b) that it does not
affect only whites in northern Europe or
immigrants from these countries living in
other parts of the world.
In addition, based on the new data on the
deficiency allele frequencies and prevalence
for PiS and PiZ worldwide (de Serres 2002),
we can conclude that AAT deﬁciency is a not
a rare disease but is a disease that has been
rarely diagnosed. The major conclusion of this
study (de Serres 2002) was that AAT defi-
ciency is not rare but actually may be one of
the most common single-locus genetic diseases
in the world.
Most important is the unique susceptibility
of AAT-deficient individuals to exposure to
chemical and particulate environmental agents
(Mayer et al. 2000; Sigsgaard et al. 2000).
Such exposures can result in both lung and
liver disease as well as other adverse health
effects. 
Background
Molecular genetics. The AAT gene locus is
located on the long arm of chromosome 14,
has been mapped to chromosome 14q31–32.3
(Byth et al. 1994), and is organized in three
noncoding (Ia, Ib, and Ic) exons and four (II,
III, IV, and V) coding exons (Blank and
Brantly 1994). AAT is a 52-kDa single-chain
glycoprotein composed of 394 amino acid
residues and three asparagine-linked complex
carbohydrate side chains (Brantly et al. 1988).
The normal gene is designated PiM, and at
least 100 additional normal and deficiency
alleles have been described (Brantly et al. 1988;
Crystal et al. 1989). The two most common
variant or deficiency alleles are PiS and PiZ
(Brantly 1996). The PiS allele resulted from a
single base-pair substitution in exon III of
thymidine for adenine (Glu264GAA → Val
GTA). The PiZ allele resulted from a single
base-pair substitution in exon V of adenine for
guanine (Glu342 GAG → Lys AAG) (Brantly
1996; Brantly et al. 1988). 
The phenotypes of different AAT alleles
are identiﬁed by determining their isoelectric
point (IEF) on a thin-layer polyacrylamide
gel in a pH gradient of 4–5. Major variation
in the migration of various AAT alleles is the
result of amino acid substitutions that alter
the net charge of the protein and thus the IEF
of the protein (Brantly 1996). This technique
provides a reliable detection of individuals
Environmental Health Perspectives • VOLUME 111 | NUMBER 16 | December 2003 1851
Alpha-1 Antitrypsin Deﬁciency Is Not a Rare Disease but a Disease That Is
Rarely Diagnosed
Frederick J. de Serres
Laboratory of Molecular Toxicology, Division of Intramural Research, National Institute of Environmental Health Sciences, Research
Triangle Park, North Carolina, USA
Address correspondence to F.J. de Serres, LMT,
NIEHS, MD-F1-06, PO Box 12233, Research
Triangle Park, NC 27709 USA. Telephone: (919)
541-0718. Fax: (919) 942-5305. E-mail: deserres@
bellsouth.net
This study was supported in part by the Alpha-1
Foundation, Miami (FL).
The author declares he has no competing ﬁnancial
interests.
Received 9 June 2003; accepted 9 September 2003.
Articles in the literature on alpha-1 antitrypsin (AAT) deﬁciency have been interpreted as indicat-
ing that AAT deficiency is a rare disease that affects mainly Caucasians (whites) from northern
Europe. In a recent publication on the worldwide racial and ethnic distribution of AAT deﬁciency,
new data were presented demonstrating that it is also found in various populations of African
blacks; Arabs and Jews in the Middle East; and Central, Far East, and Southeast Asians, as well as
whites in Australia, Europe, New Zealand, and North America. The new data on the prevalence of
AAT deﬁciency in other major racial groups worldwide will affect the standards for the diagnosis
of AAT deficiency by the medical community, with the realization that is not a rare disease of
whites in northern Europe and immigrants from these countries in the New World. In a total
population of 4.4 billion in the 58 countries surveyed, there are at least 116 million carriers (those
with Pi phenotypes PiMS and PiMZ) and 3.4 million with deﬁciency allele combinations (pheno-
types PiSS, PiSZ, and PiZZ) for the two most prevalent deﬁciency alleles PiS and PiZ; therefore,
the new data suggest that AAT deﬁciency may be one of the most common serious single-locus
genetic diseases in the world. Particularly important is the unique susceptibility of AAT-deﬁcient
individuals to exposure to chemical and particulate environmental agents. Such exposures are
known to result in both lung and liver disease as well as other adverse health effects. Key words:
alpha-1 antitrypsin deﬁciency, alpha-1 protease, alpha-1 protease inhibitor, genetic epidemiology,
Pi phenotypes, Pi subtypes, population genetics. Environ Health Perspect 111:1851–1854 (2003).
doi:10.1289/ehp.6511 available via http://dx.doi.org/ [Online 9 September 2003]
Research Commentarycarrying either the PiS or PiZ variant alleles.
It is important to note that the genotype of
individual AAT alleles can only be determined
by DNA sequencing.
The origin of PiS and PiZ deficiency
alleles. Gene-mapping studies have shown
that the PiZ allele probably arose in north-
ern Europe (Cox et al. 1985; Seixas et al.
2001). Age estimates of AAT variants based
on microsatellite variation suggest that the
Z deﬁciency allele appeared 107–135 genera-
tions ago and could have been spread in
Neolithic times. The PiS deficiency allele is
older, occuring 279–470 generations ago; its
high frequency in the Iberian Peninsula sug-
gests that PiS could have originated in this
region (Seixas et al. 2001). The presence of
both of these deﬁciency alleles in countries in
other parts of the world is yet to be explained.
Does their presence result from independent
mutations in the same two codons in the
AAT gene, or have the original PiS and PiZ
deﬁciency alleles been spread throughout the
world by the migrations and explorations of
different peoples?
Impact of the new data on carriers and
deficiency allele combinations worldwide.
AAT deﬁciency was discovered only in 1963
(Laurell and Eriksson 1963). The generally
accepted feeling was that it was a disease of
only white northern Europeans, where the
prevalence of PiZ is the highest (Hutchison
1998); therefore, it was not a condition for
which laboratory tests would be routinely
ordered by physicians in clinical practice. The
discovery that there are very large numbers of
carriers and deﬁciency allele combinations for
PiS and PiZ in the 11 geographic regions
studied worldwide, as well as the fact that
there are nonwhites affected by this disease,
will have a major effect on the diagnosis of
individuals with AAT deﬁciency by the medi-
cal community. The ﬁrst consequence is that
AAT deﬁciency may well affect diagnosis and
treatment of nonwhites who seek medical
treatment for allergies or asthma. The second
consequence is that educational programs
must be developed to train physicians in clini-
cal practice to test patients for this disease.
Sources of information on AAT deﬁciency.
Searches of the medical literature on AAT
deficiency on PubMed (National Library of
Medicine, Bethesda, MD) and Web of
Science (Institute for Scientific Information,
Phildelphia, PA) from 1965 to 2003 have
resulted in the development of a bibliography
of almost 12,500 references, which is available
on the Alpha-1 Foundation website (Alpha-1
Foundation 2003). Particularly useful are four
excellent reviews of AAT deﬁciency (Brantly
1996; Crystal 1996; Fagerhol and Cox 1981;
WHO 1996). In this article, I present pri-
mary facts of this disease in order to improve
understanding of AAT deﬁciency.
ATT Deﬁciency and Health
Physiology. AAT is a protein produced mainly
by the liver and to a lesser extent by mono-
nuclear phagocytes, which are present in blood
and tissues throughout the body. Although
named for its ability to inhibit the action of the
protease trypsin, AAT is thought to function
physiologically as a primary inhibitor of elas-
tase, a powerful neutrophil-derived protease.
AAT also inhibits other serine proteases
(Crystal 1996) and consequently is also known
as “alpha1-proteinase inhibitor.” This neu-
trophil elastase is an omnivorous protease that
can result in “genetic emphysema” from dam-
age primarily to the lower lobes of the lungs
(Pierce 1988), as well as liver disease, which is
expressed as neonatal cholestasis that may
progress to juvenile cirrhosis and slowly pro-
gressive liver disease in the adult (Mahadeva
and Lomas 1998).
Clinical manifestations. The clinical mani-
festations of AAT deficiency vary widely
among individuals, ranging from asympto-
matic in some to fatal liver or lung disease in
others (Hutchison 1988). The lung manifesta-
tions of AAT deﬁciency include emphysema,
chronic bronchitis, chronic obstructive pul-
monary disease (COPD), bronchiectasis, and
asthma. Emphysema usually develops by the
ﬁfth to sixth decade in affected individuals but
commonly appears in the fourth decade in
individuals who smoke (Brantly et al. 1988;
Janus et al. 1985). The liver manifestations
include hepatitis, cirrhosis, hepatocarcinoma,
and liver failure. The presence of a particular
abnormal AAT allelic variant, PiZ, is strongly
associated with liver disease. However, how
this genetic abnormality results in abnormali-
ties in the liver is not known. In addition, the
natural history and course of AAT defi-
ciency–associated liver disease have not been
adequately defined. In rare cases, AAT defi-
ciency can result in necrotizing panniculitis
(a skin disease resulting from an inflamma-
tory response with typical necrotic lesions in
the subcutis and dermis, which can be exten-
sive), for which there is little or no effective
treatment (O’Riordan et al. 1997), as well as
vasculitis (Bazex et al. 2002).
Genetic epidemiology. The presumed inci-
dence of AAT deficiency (e.g., phenotype
PiZZ) has been estimated by others (Cox et al.
1987; Tobin et al. 1983) at about 1/4,000 live
births among individuals in the United States.
Thus, AAT deﬁciency was believed to be sec-
ond in frequency only to cystic ﬁbrosis, which
occurs in approximately 1/2,500 live births
among whites in this same population. New
data based on control cohort data on the popu-
lation of the United States indicate that the
incidence of AAT deﬁciency for all ﬁve pheno-
typic classes of the PiS and PiZ deﬁciency alle-
les (PiMS, PiMZ, PiSS, PiSZ, and PiZZ) is 1
in 9.8 for Canada and 1 in 11.3 for the United
States (de Serres et al. In press). Comparable
studies of countries in southern Europe indicate
marked variation in the total frequency of all
ﬁve phenotypic classes: 1 in 3.8 for Portugal,
1 in 4.4 for Spain, 1 in 6.3 for France, and 1 in
13.4 for Italy (de Serres et al. 2003). 
These new data support the general
impression of the scientiﬁc community (WHO
1996) that AAT deficiency is significantly
underestimated in North America and Europe
as well as worldwide. Therefore, determination
of the true gene frequencies and gene preva-
lences of PiS and PiZ, the most common
abnormal AAT alleles, in addition to factors
affecting phenotypic penetrance are high pri-
orities of those groups that support screening
and detection programs.
Pathogenesis. The pathophysiologic basis
of emphysema in individuals with AAT deﬁ-
ciency is currently thought to be a secondary
consequence of the reduction in serum and
tissue AAT levels. In the lung, repeated expo-
sure to microbial pathogens and/or other
inﬂammatory stimuli that result in neutrophil
recruitment and activation increases the burden
of free neutrophil elastase activity in the lung.
The consequence of the latter, unopposed by
an effective antiprotease protective screen, is
progressive destruction of normal lung tissue
and, as a result, emphysema.
Plasma deficiency of AAT is most com-
monly due to the Z mutation (Glu342 GAG
→ Lys AAG) and is associated with early-
onset panlobular emphysema. Reduced AAT
levels (~10–15% of normal) result in a com-
promised “protective screen” of antiprotease
activity. The local deﬁciency of Z AAT is exac-
erbated by the formation of polymers within
the lung (Lomas 2000), and data now show
that this polymerization not only inactivates
AAT but also converts the molecule to a
chemoattractant for human neutrophils
(Parmar et al. 2002). The chemotactic proper-
ties of polymeric AAT may explain the exces-
sive numbers of neutrophils found in the
lungs of Z AAT homozygotes and suggest a
new paradigm for the pathogenesis of emphy-
sema in these patients (Parmar et al. 2002).
The liver is thought to be the predominant
source of AAT in the blood and tissues, with a
somewhat lesser contribution from circulating
and tissue mononuclear phagocytes. In some
forms of AAT deficiency, liver cells have
reduced secretion of the abnormal AAT.
However, the reduction in serum and/or tissue
AAT protein levels has not been identiﬁed as a
determinant of the liver pathology. Rather, the
accumulation of abnormal AAT (i.e., in the
case of the PiZ-type AAT allele) is thought to
initiate the pathologic response leading to juve-
nile and adult cirrhosis as well as hepatocellular
carcinoma as a result of its accumulation in the
endoplasmic reticulum of hepatocytes (Lomas
et al. 1992). The association of other abnormal
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clearly associated with liver disease.
There are several current theories about
how such abnormal accumulation might trans-
late into hepatocellular damage (Marcus et al.
1998). A better understanding of the molecu-
lar biology of AAT gene expression and protein
folding as well as intracellular and extracellular
responses to expression of abnormal AAT has
recently led to identiﬁcation of novel potential
targets of therapy (Carrell and Lomas 2002).
Adverse health effects of PiS and PiZ.
Recent review articles (Feld 1989; Gourley
et al. 1989) and research articles (Sandford et
al. 1999; Sigsgaard et al. 2000) provide docu-
mentation that both carriers (PiMS and PiMZ)
and deﬁciency allele combinations (PiSS, PiSZ,
and PiZZ) are at risk for various adverse health
effects. The adverse health effects associated
with being a carrier of the PiS defective allele
were reviewed in 1989 (Gourley et al. 1989),
and they included cirrhosis (Lieberman et al.
1975), multiple sclerosis (Lolin and Ward
1995), chronic “cryptogenic” liver disease
(Carlson and Eriksson 1985), and malignant
hepatoma (Carlson and Eriksson 1985). In
addition, there are more recent reports that the
PiMS phenotype can be associated with
hepatic dysfunction during the ﬁrst 6 months
of life (Pittschieler 1994), to cryptogenic cir-
rhosis between ages 1 month and 18 years
(Lima et al. 2001), and intracranial arterial dis-
sections (Schievink et al. 1998).
In other publications, PiMZ carriers were
found to be more prone to the development of
COPD (Lieberman et al. 1986) and to
chronic liver failure as adults (Graziadei et al.
1998). In addition, carriers for both defective
alleles have been found to be at risk for the
development of asthma (Colp et al. 1993) and
of alcoholic toxic cirrhosis (Spitsyn et al.
2001).The fact that carriers for various meta-
bolic diseases such as early vascular disease in
homocystinuria, hyperammonemic episodes in
ornithine transcarbamylase deﬁciency, prese-
nile cataracts in galactosemia, and so forth
(Endres 1997), as well as for AAT deﬁciency
(Feld 1989; Gourley et al. 1989), are at risk
for adverse health effects has been well docu-
mented. Additional evidence for the risk of
developing adverse health effects for carriers of
AAT deficiency can also be found in more
recent reviews (Gourley et al. 1989; Stoller
et al. 2003).
New research initiatives are needed to gain
a better understanding of the differences in the
adverse health effects associated with the same
five phenotypic classes of AAT deficiency in
different individuals associated with the two
most prevalent deﬁciency alleles, PiS and PiZ.
Equally important is the need to investigate
any differences associated with the expression
of this genetic disease in different racial sub-
groups. Such an approach may well resolve
apparent differences in the adverse health
effects reported in the medical literature on
each of the ﬁve phenotypic classes of the PiS
and PiZ deﬁciency alleles.
Current therapy. The current approach to
speciﬁc therapy for individuals with lung dis-
eases related to AAT deficiency involves
administration of the normal AAT protein.
This replacement usually involves weekly or
biweekly infusion with a derived pooled
human blood product containing normal AAT
(Dirksen et al. 1999; Lieberman 2001). Other
therapeutic measures include nonspecific or
supportive measures for the clinical manifesta-
tions of liver or lung disease. In severe cases of
liver or lung disease, transplantation has been
used successfully in selected cases (Fischer et al.
2002; Kayler et al. 2002). Moreover, liver
transplantation is a therapeutic option for
some patients with advanced liver disease.
Risk Factors
Smoking as a risk factor for emphysema.
Smoking is the most important risk factor for
the development of emphysema in AAT deﬁ-
ciency of the PiZZ type. In a British study
(Hutchison and Cooper 2002), homozygotes
for Pi type Z were identified among chest
clinic patients and close relatives. Clinical and
lung function data were obtained by means of
a standardized questionnaire administered
yearly for a maximum of 15 years. Forced
expiratory volume in 1 sec (FEV1) and vital
capacity were studied in 194 PiZZ patients at
registration. Past or present smoking history
had the strongest relationship to reduction in
FEV1 (p < 0.001), but among those who had
smoked, estimated total lifetime tobacco con-
sumption (kilograms) was not significantly
related to FEV1. 
In a Danish study on never-smoking non-
index cases of phenotype PiZZ, no abnormal-
ities in lung function could be identified
(Seersholm et al. 1994). The annual decline
of FEV1 in smokers with AAT deficiency is
approximately 130 mL compared with 70 mL
in ex-smokers (Seersholm et al. 1995). A later
series (Piitulainen and Eriksson 1999) showed
mean declines of 70 mL/year in current
smokers, 47 mL in never-smokers, and 41 mL
in ex-smokers, indicating similar decline rate
in nonsmokers and ex-smokers.
In another British study, Hutchison et al.
(1987) found an overall FEV1 decline of
55 mL/year with no effect of smoking cessa-
tion. In a joint American and Swedish study,
Buist et al. (1983) estimated the FEV1 decline
to be 100 mL/year, and Janus et al. (1985)
found a FEV1 decline of 316 mL/year in
smokers and 80 mL/year in never smokers.
These two studies did not evaluate the effect
of smoking cessation, but concurred that
smoking is the most important risk factor for
adverse lung effects from AAT deﬁciency.
Environmental chemicals and particulates.
The role of polymorphisms in the human
genome in modifying the effects of exposures
to toxic environmental agents has been dis-
cussed in a recent review in a broader context
(Kelada et al. 2003).
Regarding AAT deﬁciency, questions exist
as to whether there is an increased risk for
adverse health effects when such individuals
with AAT deﬁciency are exposed to toxic envi-
ronmental agents (Mayer et al. 2000; Sigsgaard
et al. 2000). Occupational exposures of concern
may include a variety of work situations that
expose workers with AAT deficiency to haz-
ardous agents. Such agents (and worker groups
exposed) could include chemical substances
(beauticians, chemical plant workers, fumiga-
tors, gas station attendants, painters, and
welders), toxic fumes (airport personnel; bus,
cab, and truck drivers; dry cleaners; factory
workers; industrial and household cleaners; and
manicurists), and organic wastes and/or partic-
ulates (agricultural workers, dental workers,
farmers, miners, and textile workers). Those at
risk also may work in professions regularly
exposed to pathogens and other readily trans-
missible diseases (doctors, school teachers,
nurses and other health care professionals, sales
personnel, and restaurant and hotel wait staffs).
The collection of detailed information on occu-
pation is critical for the effective management
of individuals with AAT deﬁciency.
Conclusions
The new data on the incidence of AAT deﬁ-
ciency worldwide and the suggestion that it
may be the most common single gene heredi-
tary disease for humans mandate the develop-
ment of better mechanisms for effective
diagnosis and treatment. The large numbers of
AAT deficiency carriers and those with defi-
ciency allele combinations for the two most
common alleles PiS and PiZ worldwide clearly
indicate that most carriers and deﬁciency allele
combinations for PiS and PiZ have not been
diagnosed. The fact that this disease is not just a
disease of white northern Europeans but affects
essentially all racial subgroups worldwide
impacts the commonly accepted standards for
diagnosis of AAT deﬁciency by general practi-
tioners and such specialists as allergists and pul-
monary and hepatic physicians. Particularly
important is the unique sensitivity of AAT-
deﬁcient individuals to exposure to chemical
and particulate environmental agents.
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